Image

HIV Exposure In Utero and Metabolic Disease Risk in HIV-Negative Young Adults

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

Globally, over 1 million babies are born to mothers with HIV each year. With the advent of prenatal antiretroviral therapy, up to 98% of these individuals may be HIV-exposed uninfected (HEU). A growing literature suggests that in utero HIV exposure - even in the absence of subsequent infection - may be associated with adverse health outcomes in infancy and childhood. However, there is little information about the long-term health implications of in utero HIV exposure later in life, such as into adulthood. In this study, for the first time, we seek to prospectively evaluate metabolic and immune indices among HEU young adults as compared to well-matched HIV-unexposed uninfected controls. This study serves as a necessary first step toward optimizing clinical care for this expanding and aging HEU population, including the implementation of novel screening and prevention strategies.

Eligibility

INCLUSION CRITERIA:

HIV-Exposed Uninfected (HEU) Mother-Young Adult Dyads

  1. Male or female young adult, 18-30 years old
  2. Documentation of HIV infection in mother with date of diagnosis preceding young adult birth date
  3. Negative HIV test in young adult

Control Mother-Young Adult Dyads

  1. Matching to HEU dyad
  2. Negative HIV test in mother and young adult

EXCLUSION CRITERIA:

All Young Adults

  1. History of being adopted
  2. Pregnancy within 6 months or active nursing
  3. Change in blood glucose or blood pressure medication within 3 months
  4. Change in estrogen or testosterone therapy within 3 months
  5. Glucocorticoids (except steroid inhalers or creams) within 3 months
  6. Antiretroviral therapy use within 6 months (i.e., prophylaxis)

Study details

HIV-exposed Uninfected

NCT04132830

Massachusetts General Hospital

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.